Sweden’s largest daily financial newspaper, Dagens Industri (DI), today published an article about VERIGRAFT. 

For the original article in Swedish, klick here.

See translation below:

“How VERIGRAFT changes lives and the future of healthcare

A challenge in transplantation is the recipient’s immune system rejecting the new tissue—but new technology creating personalized tissue can address this issue.

– We have achieved outstanding initial results from our ongoing Phase 1/2 trial,
says Petter Björquist, CEO of VERIGRAFT, who plans to finance continued work through crowdfunding.

Medical transplants have revolutionized healthcare, but there are challenges.
One of these is the risk of the new tissue being rejected. The patient’s immune
system may recognize the transplanted organ as foreign and attack it. To avoid
this, lifelong immunosuppressive drugs are required, which have serious side
effects and increase the risk of infections and other diseases, such as cancer.

VERIGRAFT has developed a technology where tissue is taken from a donor,
cleansed of cells and DNA, and then personalized using a small amount of
the patient’s blood.

– This eliminates the risk of rejection and the need for lifelong medical treatment,
explains Petter Björquist.

The process takes only ten days, compared to the up to six months currently
required to personalize tissue. And this is achieved at a fraction of the cost.

Leg ulcers healed in a short time
Initially, VERIGRAFT has focused on the possibility of using the technology to
replace damaged valves in blood vessels in the groin, a condition that causes
leg ulcers. A Phase 1/2 study in Spain shows very promising results.

– Patients who have had large, open, and bleeding leg ulcers for years have seen
their wounds heal within weeks to a few months with our treatment, he says.

Simultaneously, VERIGRAFT is developing methods to use the technology for
damaged arteries, heart valves, and nerves.

To fund its continued work, VERIGRAFT has opened the possibility for the public
to invest in its operations through crowdfunding.

– We are offering private investors just over two percent of the company. We
believe we have enormous potential, concludes Petter Björquist.

Facts
VERIGRAFT has a strategically focused research and development pipeline and
aims to commercialize a range of products in a global market. With its technology,
VERIGRAFT has the potential to cure diseases that currently lack treatment,
thereby transforming the lives of thousands of patients. The company has a strong
foundation of innovation with over 80 approved patents worldwide.”